Big names like the Cleveland Clinic and Mass General Brigham in Boston say they'll pass on it for now. One neurology practice has even banned Biogen sales reps.
The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works. Several major medical centers remain undecided on whether to use
Persistent concerns about the first new Alzheimer’s treatment in more than 20 years are curbing access more than four months after regulators approved it
The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed